Ebrantil, 5 mg/ml 5 pcs

The drug Ebrantil reduces BP and BP in a balanced manner, reducing peripheral resistance.

Urapidil reduces pre- and post-load on the heart, increases the efficiency of the heart contraction, thus, in the absence of arrhythmia, the drug increases the reduced cardiac output.

The mechanism of action. The drug Ebrantil has central and peripheral mechanisms of action.

Predominantly blocks peripheral postsynaptic α₁-adrenoreceptors, i.e. the drug blocks vasoconstrictor action of catecholamines.

In the CNS, urapidil affects the activity of the vasomotor center, which is manifested in the prevention of reflex changes in the tone of the sympathetic nervous system.

Urapidil does not affect parameters of carbohydrate metabolism, uric acid metabolism and does not cause fluid retention in the body.

Indications

refractory hypertension or its severe severity;
controlled arterial hypotension during and/or after surgery.
hypertensive crisis;

Pharmacological effect

The drug Ebrantil balancedly reduces SBP and DBP, reducing peripheral resistance.

Urapidil reduces pre- and afterload on the heart, increases the efficiency of cardiac contraction, thereby, in the absence of arrhythmia, the drug increases the reduced cardiac output.

Mechanism of action. The drug Ebrantil has central and peripheral mechanisms of action.

Predominantly blocks peripheral postsynaptic α1-adrenergic receptors, i.e. the drug blocks the vasoconstrictor effect of catecholamines.

In the central nervous system, urapidil affects the activity of the vasomotor center, which manifests itself in the prevention of reflex changes in the tone of the sympathetic nervous system.

Urapidil does not affect carbohydrate metabolism, uric acid metabolism and does not cause fluid retention in the body.

Special instructions

Possible simultaneous use with other antihypertensive drugs prescribed orally.

There are no clinical data on the use of the drug in children under 18 years of age.

Active ingredient

Urapidil

Composition

1 ml of solution for intravenous administration contains:

active ingredient:

urapidil hydrochloride 5.47 mg (corresponding to 5 mg urapidil),

excipients:

propylene glycol;

sodium hydrogen phosphate dihydrate;

sodium dihydrogen phosphate dihydrate;

water for injections

Contraindications

open duct of Botallus;
pregnancy;
hypersensitivity to the drug Ebrantil;
aortic stenosis;
lactation period (efficacy and safety have not been established);
age up to 18 years.

With caution: elderly age, impaired liver and/or kidney function, hypovolemia.

Side Effects

Most of the following side effects are caused by a sharp drop in blood pressure, but clinical experience shows that they disappear within a few minutes even after a drip infusion of the drug Ebrantil. Severe side effects may require stopping treatment.

A list of side effects indicating the frequency of their development is presented in the tables.

Side effects of the drug Ebrantil (intravenous solution)

Organ system
Frequency
Often (≥ 1:100, Sometimes (≥1:1000, < 1:100) Rarely (≥1:10000, Very rarely ( From the SSS side Palpitations, tachycardia, bradycardia, chest tightness, shortness of breath, arrhythmias From the gastrointestinal tract Nausea Vomit Laboratory indicators Thrombocytopenia* From the side of the central nervous system Dizziness, headache, fatigue Feeling restless From the reproductive system and mammary glands Priapism From the urinary system Proteinuria Nephropathy, nephrotic syndrome From the skin Increased sweating Allergic reactions (skin itching, redness of the skin, exanthema)

Interaction

The hypotensive effect of urapidil may be enhanced when taken together with α-blockers or other antihypertensive drugs, as well as during hypovolemia (nausea, vomiting) and when taking ethanol.

With simultaneous administration of cimetidine, the Cmax of urapidil in the blood plasma may increase by 15%.

Overdose

Symptoms: dizziness, orthostatic collapse, fatigue, lethargy.

Treatment: if there is a sharp drop in blood pressure, it is necessary to elevate the patient’s legs and begin infusion therapy to increase blood volume. If these measures are ineffective, you can start infusion of vasoconstrictors under blood pressure control. In very rare cases, intravenous administration of catecholamines (0.5–1 mg of epinephrine (adrenaline) diluted in 10 ml of saline) is necessary.

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

2 years

Manufacturer

Takeda Austria GmbH, Austria